Bai D, Kim H, Wang P
Med Chem Res. 2024; 33(8):1292-1306.
PMID: 39132259
PMC: 11315725.
DOI: 10.1007/s00044-024-03227-x.
Lin Y, Zimmermann J, Schulke S
Front Immunol. 2024; 15:1348305.
PMID: 38464539
PMC: 10920236.
DOI: 10.3389/fimmu.2024.1348305.
Yuan W, Wang Z, Zou Y, Zheng G
Biomedicines. 2024; 12(2).
PMID: 38398070
PMC: 10887094.
DOI: 10.3390/biomedicines12020469.
Wang P
Vaccines (Basel). 2021; 9(3).
PMID: 33807582
PMC: 8001307.
DOI: 10.3390/vaccines9030222.
Pifferi C, Fuentes R, Fernandez-Tejada A
Nat Rev Chem. 2021; 5(3):197-216.
PMID: 33521324
PMC: 7829660.
DOI: 10.1038/s41570-020-00244-3.
Carbohydrate Immune Adjuvants in Subunit Vaccines.
Bashiri S, Koirala P, Toth I, Skwarczynski M
Pharmaceutics. 2020; 12(10).
PMID: 33066594
PMC: 7602499.
DOI: 10.3390/pharmaceutics12100965.
Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
Fernandez-Tejada A, Tan D, Gin D
Acc Chem Res. 2016; 49(9):1741-56.
PMID: 27568877
PMC: 5032057.
DOI: 10.1021/acs.accounts.6b00242.
Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.
Fernandez-Tejada A, Tan D, Gin D
Chem Commun (Camb). 2015; 51(73):13949-13952.
PMID: 26243268
PMC: 4643164.
DOI: 10.1039/c5cc05244k.
Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.
Fernandez-Tejada A, Chea E, George C, Gardner J, Livingston P, Ragupathi G
Bioorg Med Chem. 2014; 22(21):5917-23.
PMID: 25284254
PMC: 4410046.
DOI: 10.1016/j.bmc.2014.09.016.
Development of a minimal saponin vaccine adjuvant based on QS-21.
Fernandez-Tejada A, Chea E, George C, Pillarsetty N, Gardner J, Livingston P
Nat Chem. 2014; 6(7):635-43.
PMID: 24950335
PMC: 4215704.
DOI: 10.1038/nchem.1963.
Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.
Cavanagh D, Kocken C, White J, Cowan G, Samuel K, Dubbeld M
PLoS One. 2014; 9(1):e83704.
PMID: 24421900
PMC: 3885447.
DOI: 10.1371/journal.pone.0083704.
Malaria vaccine research and development: the role of the WHO MALVAC committee.
Targett G, Moorthy V, Brown G
Malar J. 2013; 12:362.
PMID: 24112689
PMC: 4021081.
DOI: 10.1186/1475-2875-12-362.
Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.
Cech P, Aebi T, Abdallah M, Mpina M, Machunda E, Westerfeld N
PLoS One. 2011; 6(7):e22273.
PMID: 21799810
PMC: 3142124.
DOI: 10.1371/journal.pone.0022273.
Design and synthesis of potent Quillaja saponin vaccine adjuvants.
Adams M, Damani P, Perl N, Won A, Hong F, Livingston P
J Am Chem Soc. 2010; 132(6):1939-45.
PMID: 20088518
PMC: 2820154.
DOI: 10.1021/ja9082842.
Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.
Kaba S, Price A, Zhou Z, Sundaram V, Schnake P, Goldman I
Clin Vaccine Immunol. 2008; 15(11):1674-83.
PMID: 18784343
PMC: 2583527.
DOI: 10.1128/CVI.00164-08.
The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
Hui G, Hashimoto C
Vaccine. 2007; 25(51):8549-56.
PMID: 18006124
PMC: 2211737.
DOI: 10.1016/j.vaccine.2007.10.010.
A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
Genton B, Pluschke G, Degen L, Kammer A, Westerfeld N, Okitsu S
PLoS One. 2007; 2(10):e1018.
PMID: 17925866
PMC: 2001290.
DOI: 10.1371/journal.pone.0001018.
Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates.
Qian F, Wu Y, Muratova O, Zhou H, Dobrescu G, Duggan P
Vaccine. 2007; 25(20):3923-33.
PMID: 17428587
PMC: 1940062.
DOI: 10.1016/j.vaccine.2007.02.073.
Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.
Patel J, OCarra R, Jones J, Woodward J, Mumper R
Pharm Res. 2006; 24(2):343-52.
PMID: 17180725
DOI: 10.1007/s11095-006-9154-7.
The rational design of vaccines.
Bramwell V, Perrie Y
Drug Discov Today. 2005; 10(22):1527-34.
PMID: 16257375
PMC: 7108399.
DOI: 10.1016/S1359-6446(05)03600-7.
